CWM Advisors LLC Has $292,000 Holdings in Amneal Pharmaceuticals, Inc. (NYSE:AMRX)

CWM Advisors LLC lessened its position in Amneal Pharmaceuticals, Inc. (NYSE:AMRX) by 6.3% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 43,392 shares of the company’s stock after selling 2,922 shares during the period. CWM Advisors LLC’s holdings in Amneal Pharmaceuticals were worth $292,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in AMRX. Morgan Stanley grew its stake in Amneal Pharmaceuticals by 187.9% in the third quarter. Morgan Stanley now owns 251,038 shares of the company’s stock valued at $974,000 after acquiring an additional 163,848 shares during the period. Strs Ohio grew its stake in Amneal Pharmaceuticals by 24.8% in the third quarter. Strs Ohio now owns 144,100 shares of the company’s stock valued at $559,000 after acquiring an additional 28,600 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Amneal Pharmaceuticals by 1,231.9% during the fourth quarter. Assenagon Asset Management S.A. now owns 247,725 shares of the company’s stock valued at $1,132,000 after buying an additional 229,125 shares during the last quarter. Hussman Strategic Advisors Inc. boosted its position in shares of Amneal Pharmaceuticals by 20.6% during the fourth quarter. Hussman Strategic Advisors Inc. now owns 123,000 shares of the company’s stock valued at $562,000 after buying an additional 21,000 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its position in shares of Amneal Pharmaceuticals by 75.4% during the fourth quarter. Victory Capital Management Inc. now owns 171,239 shares of the company’s stock valued at $783,000 after buying an additional 73,602 shares during the last quarter. 33.49% of the stock is owned by hedge funds and other institutional investors.

In other news, EVP Joseph Todisco sold 36,330 shares of the firm’s stock in a transaction on Monday, March 15th. The stock was sold at an average price of $6.82, for a total value of $247,770.60. Following the transaction, the executive vice president now directly owns 316,270 shares in the company, valued at approximately $2,156,961.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 26.32% of the company’s stock.

Several research analysts recently issued reports on the company. The Goldman Sachs Group raised Amneal Pharmaceuticals from a “sell” rating to a “buy” rating and lifted their target price for the company from $4.00 to $6.50 in a research report on Monday, March 15th. Guggenheim lifted their target price on Amneal Pharmaceuticals from $6.50 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, April 14th. TheStreet raised Amneal Pharmaceuticals from a “d” rating to a “c-” rating in a research report on Tuesday, May 4th. Barclays lifted their target price on Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a research report on Monday, March 1st. Finally, Zacks Investment Research upgraded Amneal Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a report on Monday, May 10th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $7.13.

Shares of Amneal Pharmaceuticals stock opened at $5.64 on Friday. The firm has a market capitalization of $1.69 billion, a P/E ratio of 13.76, a price-to-earnings-growth ratio of 0.29 and a beta of 1.27. The business’s fifty day simple moving average is $5.96 and its 200 day simple moving average is $5.16. The company has a current ratio of 2.31, a quick ratio of 1.60 and a debt-to-equity ratio of 8.20. Amneal Pharmaceuticals, Inc. has a 12 month low of $3.45 and a 12 month high of $7.45.

Amneal Pharmaceuticals (NYSE:AMRX) last issued its earnings results on Thursday, May 6th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.18 by $0.02. Amneal Pharmaceuticals had a return on equity of 42.02% and a net margin of 3.30%. The firm had revenue of $493.10 million for the quarter, compared to analyst estimates of $514.73 million. During the same period in the previous year, the company posted $0.20 earnings per share. The business’s revenue was down 1.1% on a year-over-year basis. Analysts predict that Amneal Pharmaceuticals, Inc. will post 0.56 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

See Also: Basic Economics creates winners and losers

Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc. (NYSE:AMRX).

Institutional Ownership by Quarter for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.